Oportuzumab monatox DLRC Pharma Services (oportuzumab monatox)
- Region
- 🇪🇺 EU
- Active substance
- oportuzumab monatox
- Company
- DLRC Pharma Services Ltd
- Status
- Application withdrawn
- Therapeutic area
- Urologic Neoplasms; Urinary Bladder Neoplasms
- Application
- EMEA/H/C/005730
- ATC
- L01FX06
- Official record
- www.ema.europa.eu
Indication
Treatment and prevention of recurrence of carcinoma-in-situ (CIS) of the urinary bladder and prevention of recurrence of high grade Ta and/or T1 papillary tumours
Regulatory milestones
No milestones recorded in the last year.
Follow Oportuzumab monatox DLRC Pharma Services
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.